Published: 05/1/2026 | Author: Quentin Blount

For millions of Americans managing chronic pain, the choice has long felt impossible: live with debilitating pain or risk opioid addiction. A new compound identified by researchers offers a potential third option: DFNZ. But the road from the lab to the medicine cabinet is long, and people are suffering now.

The Impossible Choice for Chronic Pain Patients

The opioid crisis didn’t start in darkened back alleys. It began in doctor’s offices, where patients with legitimate, life-altering pain were prescribed medications that worked, so much so that they didn’t let go.

Let’s be clear. Most people don’t start out wanting to get addicted. Rather, those with chronic pain often can’t get out of bed, go to work, or parent their children. Doctors handed them prescriptions that offered relief and dependence in the same bottle.

Up to 12% of patients who’ve used opioids for chronic pain develop addictions. This statistic sounds manageable until you apply it to tens of millions of prescriptions. A large fraction of patients currently suffering from opioid use disorder and dying from opioid overdoses had their first exposure as pain patients.

This tragedy lies at the center of the opioid epidemic that DFNZ researchers are trying to solve.

About DFNZ and Opioid Addiction

Researchers at the National Institute on Drug Abuse (NIDA), led by Dr. Michael Michaelides, have identified a novel synthetic compound called N-desethyl-fluornitrazene—DFNZ for short—that relieved pain in rodents without causing tolerance or other indicators of potential addiction.

In animal studies, DFNZ produced robust relief for acute and inflammatory pain. The novel drug didn’t cause significant respiratory depression or meaningful withdrawal effects with repeated dosing. 

NIDA Director Dr. Nora D. Volkow reported that “developing a highly effective pain medication without these drawbacks would have enormous public health benefits.”

For chronic pain patients who have watched their prescription opioid dose climb over time, with tolerance building and withdrawal lurking, that statement carries enormous weight.

Chronic Pain Becomes Opioid Addiction

Chronic pain patients become so vulnerable to narcotic addiction because opioids interact with the brain over time. Research shows that opioid addiction primarily results from damage to the amygdala, leading to irregular reward-stress functions and heightened negative emotions during withdrawal that perpetuates the addiction cycle.

The cycle is cruel. Pain demands relief, opioids provide it, tolerance develops, higher doses are needed, and withdrawal becomes added suffering layered on top of the original pain. Many chronic pain patients describe not knowing where their pain ends and their opioid dependence begins.

Although alternatives to opioids exist to manage chronic pain, many people still fall back on prescriptions. Here’s where DFNZ, if it delivers on its early promise, can break this cycle at the molecular level.

DFNZ Differs From Fentanyl and Other Opioids

DFNZ activates the μ-opioid receptor, which is the same one targeted by morphine and fentanyl. The difference is that DFNZ doesn’t trigger the dopamine-driven reinforcement that leads to opioid addiction. This challenges the long-held assumption that strong μ-opioid activation inevitably causes dependence.

DFNZ belongs to a class of compounds roughly 1,000 times more potent than morphine, yet showing remarkably few adverse effects in preclinical models. For chronic pain sufferers who’ve built tolerance to regular opioids and require stronger doses for the same relief, the implications are significant.

Experts Urge Caution

History demands measured optimism. Oxycodone was once hailed as a safer, less addictive opioid. That promise contributed to the worst drug epidemic in American history.

Neuroscientists acknowledged DFNZ as a “promising approach,” but noted important limitations to address to avoid repeating the mistakes that led to the opioid crisis.

Significant additional research and regulatory scrutiny are required before any compound like DFNZ could reach the market. Human trials, FDA review, and years of post-market surveillance lie between today’s rodent data and a prescription pad. 

But for chronic pain patients with opioid addiction today, that timeline means more time  managing the pain and the drugs that have impacted their lives and those of loved ones.

Finding Help for Opioid Addiction While Managing Chronic Pain

Here’s where you can take steps today, rather than wait. If you’re living with chronic pain and opioid addiction, you’re not alone and you’re not to blame.

The first step often includes reaching out to your community for help and guidance. Going to grassroots, local groups for peer support works. Narcotics Anonymous offers anonymous, no-cost resources, sympathetic ears and shoulders, and assurance that you have help every step of the way. 

Getting started now is easier than it might seem. Call 800-934-1582(Sponsored) or browse our directory for comprehensive listings for group listings across the country.